Chris Hollowood
InvestorChief Executive Officer of Syncona Investment Management Ltd. at Syncona
About
Chris Hollowood is Chief Executive Officer of Syncona Investment Management Ltd., having joined Syncona at its 2012 launch and served as Chief Investment Officer until 2022. He has over 20 years of life science investment experience and has led the development of Syncona's gene therapy strategy, founding companies in ocular, hepatic, renal and central nervous system therapeutics. He previously worked at Apposite Capital LLP, Bioscience Managers Ltd, Neptune Investment Management Ltd and in the pharmaceutical industry, and holds a degree in Natural Sciences and a PhD in Organic Chemistry from the University of Cambridge.
Invests in
BiotechMedical Devices
Deals · 1
Gyroscope Therapeutics LtdBoard seat
via Syncona · filed Apr 2021 · $148M raise
Attribution from SEC filings, press coverage, and firm rosters.
